NeuroPointDX, our neurological disorders division, employs our metabolomics platform and expertise in stem cell modeling to identify biomarkers. These biomarkers are useful for the diagnosis of neurological disorders as well as drug development and clinical trial patient stratification. Our work is relevant to many types of neurological disorders that are hard to diagnose and treat, including autism spectrum disorder (ASD), schizophrenia, depression, and anxiety.
NeuroPointDX is developing a blood test that can provide earlier diagnosis and more precise treatment of ASD through its clinical study, based on the child’s own metabolism. The Children’s Autism Metabolome Project (CAMP) is enrolling 1,500 children between the ages of 18 and 48 months. Participants include children diagnosed with ASD and other developmental delays, as well as typically-developing children. This study is funded by a grant from the National Institutes of Mental Health and investment by the Nancy Lurie Marks Family Foundation.